title: In vitro activity of iclaprim and comparison agents tested against Neisseria gonorrhoeae including medium growth supplement effects.
abstract: Iclaprim is a novel diaminopyrimidine currently in phase III clinical development. This study was conducted to determine the activity of iclaprim compared with trimethoprim and other commonly prescribed drug classes against a comprehensive collection of 156 Neisseria gonorrhoeae, including subsets of organisms resistant to beta-lactams and fluoroquinolones (>60%). Iclaprim (MIC(50/90), 4/8 microg/mL) was 16-fold more potent than trimethoprim (MIC(50/90), 64/>64 microg/mL), and medium growth supplements did not adversely influence activity. Lack of cross-resistances for iclaprim with other commonly used therapies could make iclaprim an alternative for several sexually transmitted diseases (gonococci, Chlamydia trachomatis).
authors.affiliation: JMI Laboratories, North Liberty, IA 512317, USA. ronald-jones@jmilabs.com
authors.forename: Ronald N
authors.initials: RN
authors.lastname: Jones
authors.forename: Douglas J
authors.initials: DJ
authors.lastname: Biedenbach
authors.forename: Helio S
authors.initials: HS
authors.lastname: Sader
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D009344:Neisseria gonorrhoeae / Q000187:drug effects*; D011743:Pyrimidines / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D011743:Pyrimidines; C486448:iclaprim